PEPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
PepGen Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.70+0.10 (+3.85%)
Close on Oct 19, 2026
- Market cap
- $186.85M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -67.4% | |
| Return on assets | – | – | -55.2% | |
| Current ratio | – | – | 11.94 | |
| Diluted shares | – | – | 42M |
Where the cash went
Fiscal 2021 to 2025, five years combined
PepGen generated $314.87M from operations and spent $7.62M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$314.87M
Used
$7.62M
Capital expenditure$7.62M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$89.66M
- Cash generatingOperating cash flow above zero-$81.64M
- Return on assets improvedROA up on the prior year-62.9% → -59.4%
- Earnings backed by cashOperating cash flow above net income-$81.64M vs -$89.66M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.41 → 11.94
- No dilutionShare count did not rise32M → 42M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –